Cargando…
Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant
Emergence of SARS-CoV-2 variants, including the globally successful B.1.1.7 lineage, suggests viral adaptations to host selective pressures resulting in more efficient transmission. Although much effort has focused on Spike adaptation for viral entry and adaptive immune escape, B.1.1.7 mutations out...
Autores principales: | Thorne, Lucy G, Bouhaddou, Mehdi, Reuschl, Ann-Kathrin, Zuliani-Alvarez, Lorena, Polacco, Ben, Pelin, Adrian, Batra, Jyoti, Whelan, Matthew V.X., Ummadi, Manisha, Rojc, Ajda, Turner, Jane, Obernier, Kirsten, Braberg, Hannes, Soucheray, Margaret, Richards, Alicia, Chen, Kuei-Ho, Harjai, Bhavya, Memon, Danish, Hosmillo, Myra, Hiatt, Joseph, Jahun, Aminu, Goodfellow, Ian G., Fabius, Jacqueline M., Shokat, Kevan, Jura, Natalia, Verba, Klim, Noursadeghi, Mahdad, Beltrao, Pedro, Swaney, Danielle L., Garcia-Sastre, Adolfo, Jolly, Clare, Towers, Greg J., Krogan, Nevan J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202424/ https://www.ncbi.nlm.nih.gov/pubmed/34127972 http://dx.doi.org/10.1101/2021.06.06.446826 |
Ejemplares similares
-
Evolution of enhanced innate immune evasion by SARS-CoV-2
por: Thorne, Lucy G., et al.
Publicado: (2021) -
Publisher Correction: Evolution of enhanced innate immune evasion by SARS-CoV-2
por: Thorne, Lucy G., et al.
Publicado: (2022) -
Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant
por: Reuschl, Ann-Kathrin, et al.
Publicado: (2021) -
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
por: White, Kris M., et al.
Publicado: (2021) -
Target Discovery for Host-Directed Antiviral Therapies: Application of Proteomics Approaches
por: Cakir, Merve, et al.
Publicado: (2021)